Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a ‘magic bullet’ strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.
New “pseudo cell” formulation could revolutionize treatment of vitreoretinal diseases
Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences and Beijing Chaoyang Hospital have developed a new “pseudo cell” formulation
October 24, 2023